At Spain's National Cancer Centre, researchers have uncovered a quiet but consequential truth about the limits of biological translation: the human enzyme responsible for slowing cellular aging cannot simply be transplanted into other animals and expected to behave the same way. Published in April 2026, the study found that human telomerase sustains its full cellular function only in primate cells, leaving decades of mouse- and dog-based preclinical research on uncertain ground. It is a reminder that genetic kinship between species does not guarantee the deeper molecular compatibility that lif
Human telomerase shows limited cross-species function, favoring primate models
A protein that fits perfectly into the human cellular ecosystem may be incompatible with a mouse.
Mark
So the human telomerase protein worked in the test tube with cells from multiple species, but failed in living cells from most of them. Why would that be?
Mimi
Because a protein doesn't exist alone. It's embedded in a whole ecosystem of other proteins, regulatory signals, and cellular machinery. When you put human telomerase into a mouse cell, it's like putting a human organ into a mouse body—the basic chemistry might be compatible, but all the supporting systems are different.
Mark
But mice and humans are both mammals. Shouldn't the cellular machinery be similar enough?
Mimi
You'd think so. But evolution has fine-tuned these systems over millions of years. The differences that seem small at the genetic level create real incompatibilities at the functional level. Primates are close enough to humans that their cellular machinery still recognizes and supports human telomerase. Mice aren't.
Mark
This seems like it would have been obvious before now. Why did researchers keep using mice for telomerase studies?
Mimi
Because mice are cheap, fast, and ethically simpler than primates. And until someone actually tested whether human telomerase works in mouse cells, there was no proof it didn't. This study is the proof.
Mark
What happens to all the existing mouse studies on telomerase therapy?
Mimi
They become questionable. Not useless—they still tell you something about how telomerase works in general. But they don't tell you whether a therapy will work in humans. That's a hard truth for a field that's invested years and millions in mouse models.
Mark
So researchers have to move to primate studies now?
Mimi
If they want reliable data on human telomerase function, yes. Which is slower, more expensive, and ethically complicated. But it's the only way to know if you're actually testing something relevant to human biology.
The Pulse
- Decades of telomerase therapy research in mice, rats, and dogs may rest on a flawed assumption — that human cellular machinery and animal cellular machinery are interchangeable enough to predict outcomes.
- Human telomerase appeared chemically active in multiple species in vitro, creating a false confidence that collapsed the moment researchers observed what happened inside living cells.
- In mouse and dog cells, the human enzyme not only failed to lengthen telomeres but sometimes triggered cellular stress and reduced cell viability — the therapy becoming a source of harm rather than benefit.
- Only non-human primate cells — chimpanzees, macaques, and their relatives — proved capable of supporting the full biological activity of human telomerase in a living cellular environment.
- The field now faces a difficult reckoning: advancing telomerase-based therapies will require replacing fast, affordable mouse models with slower, costlier, and ethically complex primate studies.
At Spain's National Cancer Centre, researchers have uncovered a quiet but consequential truth about the limits of biological translation: the human enzyme responsible for slowing cellular aging cannot simply be transplanted into other animals and expected to behave the same way. Published in April 2026, the study found that human telomerase sustains its full cellular function only in primate cells, leaving decades of mouse- and dog-based preclinical research on uncertain ground. It is a reminder that genetic kinship between species does not guarantee the deeper molecular compatibility that life requires.
Scientists at Spain's National Cancer Centre asked what seemed like a straightforward question: could the human version of the enzyme that slows cellular aging be introduced into other animals and function the same way? The answer, published in Aging-US in April 2026, was an almost unequivocal no.
Telomerase maintains the protective caps on chromosome ends — telomeres — that shorten each time a cell divides. When they run out, cells stop dividing or die, a process central to aging. For years, researchers have tested telomerase-based therapies in mice, rats, dogs, and other animals, assuming these models could reliably predict outcomes in humans.
Raúl Sánchez-Vázquez, Paula Martínez, and their colleagues under María A. Blasco introduced the human telomerase catalytic subunit into lung cells from six mammalian species. In the test tube, results looked encouraging — the protein formed active complexes with RNA from monkey, pig, rabbit, and rat cells. But inside living cells, the picture shifted entirely. Only human and non-human primate cells showed sustained telomere lengthening. In mice, dogs, pigs, rabbits, and rats, telomeres either failed to extend or continued shortening. In some cases, the human enzyme caused cellular stress and reduced viability.
The gap between biochemical activity and biological function reveals something fundamental: telomerase does not operate in isolation. It depends on a dense network of proteins and regulatory molecules that differ between species in ways that genetic similarity alone cannot predict. A protein perfectly suited to the human cellular ecosystem may be incompatible with a mouse's, even though both are mammals.
The consequences for drug development are significant. If human telomerase does not function in mouse cells the way it does in human cells, preclinical studies using those models may not reliably forecast what will happen in patients. The researchers found that only non-human primates consistently support the full biological activity of human telomerase. Moving forward means moving away from the cheaper, faster animal models that have long dominated the field — toward primate studies that are slower, more expensive, and ethically complex. The science has narrowed the path, but it has not closed it.
Scientists at Spain's National Cancer Centre set out to answer a deceptively simple question: if you take the human version of a protein that stops cells from aging, can you drop it into other animals and have it work the same way? The answer, it turns out, is almost never.
Telomerase is the enzyme that maintains telomeres—the protective caps on the ends of chromosomes that shorten each time a cell divides. When telomeres get too short, cells stop dividing or die. This process is central to aging itself. For decades, researchers have tested telomerase-based therapies in mice, rats, dogs, rabbits, and pigs, assuming that if something works in these animals, it might work in humans. The new study, published in April 2026 in the journal Aging-US, suggests that assumption is dangerously incomplete.
Raúl Sánchez-Vázquez and Paula Martínez, working under María A. Blasco's direction, took the human telomerase catalytic subunit—the working engine of the protein—and introduced it into lung cells from six different mammalian species. They then watched what happened. In the test tube, the results looked promising. Human telomerase formed active complexes with telomerase RNA from monkey, pig, rabbit, and rat cells. The protein was biochemically functional. It should have worked.
But inside living cells, the picture changed dramatically. Only human cells and cells from non-human primates showed sustained telomere lengthening over time. The other species—pig, rabbit, rat, mouse, and dog—either failed to extend their telomeres at all or actually continued to shorten them despite the presence of active human telomerase. In mouse and dog cells, the human enzyme sometimes caused cellular stress and reduced viability. The protein was present and chemically active, yet biologically inert.
This gap between what happens in a test tube and what happens inside a cell reveals something fundamental about how life works. Telomerase doesn't function in isolation. It exists within a dense network of other proteins, regulatory molecules, and cellular machinery that differ from species to species. A protein that fits perfectly into the human cellular ecosystem may be incompatible with the equivalent system in a mouse or dog, even though both are mammals. The compatibility goes deeper than simple genetic similarity.
The implications for drug development are stark. Thousands of preclinical studies have used mice and other non-primate animals to test telomerase-based therapies for age-related diseases, cancer, and degenerative conditions. If human telomerase doesn't actually function in mouse cells the way it does in human cells, those studies may not predict what will happen in human patients. The researchers found that only non-human primates—chimpanzees, macaques, and similar species—reliably support the full biological activity of human telomerase in a cellular context.
This doesn't mean telomerase research stops. It means the path forward narrows. Developing therapies aimed at telomere-related diseases will require moving away from the cheaper, faster mouse models that have dominated preclinical research for generations. Non-human primate studies are more expensive, slower, and ethically fraught. But the science is now clear: if you want to know whether a human telomerase therapy will actually work in human cells, you need to test it in cells that are biologically similar enough to respond the same way. For this particular protein, that means primates or nothing.
Notable Quotes
Only non-human primate cells support full functional activity of the human telomerase protein in a cellular context, underscoring their suitability as preclinical models for telomerase-based therapeutic strategies.— María A. Blasco, corresponding author
Want the full story?
Read the original at News-Medical ↗
Health & Medicine